The most prevalent events were recurrent in three tumors each (1.5%) and affected a region on 17q12-q21.1, confirming the existence of a CRC subgroup with extreme ERBB2 amplification (22, 27 and 97 additional copies), and a region on 16q12.1–12.2 (23, 44 and 47 additional copies), identifying CASC16 and the transcription factor TOX3 as novel recurrently amplified genes (Table 1, Fig. 1c, Supplementary Fig. 2e). Here, CASC16 is linked to colorectal carcinoma.